Ozempic is made using genetically engineered yeast cells that produce a precursor version of its active ingredient, semaglutide. From there, the precursor goes through chemical modification, purification, and extensive quality testing before it’s filled into the pre-loaded injection pens you see at the pharmacy. The process blends biotechnology with traditional chemistry and takes place across a global network of Novo Nordisk facilities.
It Starts With Engineered Yeast
The foundation of Ozempic production is a strain of Saccharomyces cerevisiae, the same species of yeast used to brew beer and bake bread. Scientists at Novo Nordisk inserted a gene into this yeast using recombinant DNA technology so the cells would produce a specific protein: a precursor version of the semaglutide molecule. This precursor isn’t the finished drug. It’s a partial peptide backbone (covering positions 9 through 37 of the final molecule) that serves as the starting scaffold.
The yeast cells are grown in large fermentation tanks under carefully controlled conditions, where they multiply and churn out this precursor peptide. Once fermentation is complete, the precursor is recovered from the yeast cells and isolated for the next stages of production.
Chemical Modifications Build the Final Molecule
What makes semaglutide different from the GLP-1 hormone your body naturally produces is a set of deliberate chemical modifications. These changes are what allow the drug to last a full week in your body instead of being broken down in minutes.
After the precursor peptide is isolated, it goes through an acylation step. In simple terms, a fatty acid chain is attached to the peptide backbone at a specific amino acid position (Lysine 26) through a chemical linker. This fatty acid tail is what allows semaglutide to bind to a protein in your blood called albumin, which acts like a slow-release carrier, protecting the molecule from being broken down too quickly.
After acylation, a small two-part amino acid segment is chemically joined to the front end of the modified precursor, completing the full semaglutide molecule. One of these amino acids is a synthetic, non-natural building block that further protects the drug from degradation. This combination of biological production and chemical assembly is what makes semaglutide manufacturing so complex.
Purification Removes Impurities
Once the full semaglutide molecule is assembled, it needs to be separated from the byproducts, leftover reagents, and incomplete molecules that inevitably come along with the process. This is done through a series of purification steps, with reverse-phase high-performance liquid chromatography (RP-HPLC) playing a central role. The technique works by passing the mixture through a specialized column that separates molecules based on their physical and chemical properties, allowing manufacturers to isolate the pure semaglutide from everything else.
Purification is one of the most resource-intensive parts of the process. Producing just 1 kilogram of a GLP-1 receptor agonist peptide can require up to 14 metric tons of solvent, according to research published in the Journal of Organic Chemistry. For comparison, making most conventional pharmaceutical compounds uses roughly 0.3 metric tons of solvent per kilogram. The solvents commonly used in peptide manufacturing are hazardous, which adds both cost and environmental complexity.
Quality Testing Before It Leaves the Factory
Before semaglutide can be formulated into Ozempic pens, it goes through rigorous quality control. The FDA requires testing for visual appearance, identity confirmation (using both chromatography and peptide mapping), potency, uniformity across doses, and microbial purity. The finished product is also checked for high-molecular-weight proteins, which are clumps of peptide molecules that could trigger immune reactions, and for chemical impurities that might form during manufacturing or storage.
Dissolution testing confirms the drug will release properly once injected. Novo Nordisk also conducts risk assessments for elemental impurities like heavy metals, following international pharmaceutical guidelines. Every batch must meet these specifications before it can be shipped.
Fill, Finish, and the Pen Device
Once the semaglutide passes quality checks, it’s formulated into a sterile solution and filled into the pre-loaded FlexTouch injection pens. This “fill-finish” stage happens in aseptic (sterile) facilities and is a major bottleneck in production. Each pen contains multiple doses, and the filling process must maintain sterility while ensuring precise dosing accuracy. The pens are then packaged with needles and instructions for the final product that reaches pharmacies.
Scaling Up to Meet Demand
The explosion in demand for Ozempic and related semaglutide products has pushed Novo Nordisk into one of the largest pharmaceutical manufacturing expansions in history. The company spent approximately 60 billion Danish kroner (roughly $8.5 billion) on capital expenditure in 2025, up from 47 billion the year before. Most of that money went toward expanding capacity for active ingredient production and fill-finish operations.
In the United States alone, Novo Nordisk invested around $2 billion in manufacturing in 2025 and has committed a further $5.6 billion through 2028. These investments are adding new production lines, expanding existing sites, and increasing packaging capacity. The company runs its U.S. production facilities around the clock. For 2026, global capital expenditure is projected at around 55 billion Danish kroner, focused on building flexibility across every stage of the supply chain.
The Environmental Cost of Peptide Manufacturing
The massive solvent requirements of peptide manufacturing create a significant environmental challenge as production scales up. The hazardous solvents used in the process need to be carefully managed, and scaling up production using current methods could lead to an unprecedented increase in industrial waste.
The industry is working on solutions. One company developed a continuous-mode manufacturing method for peptides that reduces solvent consumption by at least 40%. Another invested nearly $266 million between 2020 and 2023 to scale up peptide production and deployed a new washing technique that cut its overall solvent use by 24% compared to 2022. These improvements matter because the gap between peptide manufacturing and conventional drug production is so large: roughly 50 times more solvent per kilogram of finished product.